Merck (MRK) Announces KEYTRUDA Phase 3 KEYNOTE-045 Met Primary Endpoint; Trial Stopped Early
Go back to Merck (MRK) Announces KEYTRUDA Phase 3 KEYNOTE-045 Met Primary Endpoint; Trial Stopped EarlyMerck & Co. (NYSE: MRK) | Delayed: 131.78 +0.03 (0.02%) | |||||
---|---|---|---|---|---|---|
Previous Close | $131.75 | 52 Week High | $65.46 | |||
Open | $132.00 | 52 Week Low | $47.97 | |||
Day High | $132.42 | P/E | 89.65 | |||
Day Low | $131.08 | EPS | $1.47 | |||
Volume | 4,424,969 |